NO980030D0 - Monoklonale antistoffer som binder CD40-L - Google Patents

Monoklonale antistoffer som binder CD40-L

Info

Publication number
NO980030D0
NO980030D0 NO980030A NO980030A NO980030D0 NO 980030 D0 NO980030 D0 NO 980030D0 NO 980030 A NO980030 A NO 980030A NO 980030 A NO980030 A NO 980030A NO 980030 D0 NO980030 D0 NO 980030D0
Authority
NO
Norway
Prior art keywords
bind
monoclonal antibodies
immunogen
disclosed
isolated antibody
Prior art date
Application number
NO980030A
Other languages
English (en)
Other versions
NO320073B1 (no
NO980030L (no
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO980030(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO980030L publication Critical patent/NO980030L/no
Publication of NO980030D0 publication Critical patent/NO980030D0/no
Publication of NO320073B1 publication Critical patent/NO320073B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19980030A 1991-10-25 1998-01-05 Antistoffer som binder CD40-L NO320073B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
NO980030L NO980030L (no) 1998-01-05
NO980030D0 true NO980030D0 (no) 1998-01-05
NO320073B1 NO320073B1 (no) 2005-10-17

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.

Country Status (13)

Country Link
EP (2) EP0667901B2 (no)
JP (2) JP3308534B2 (no)
KR (1) KR100283541B1 (no)
AT (2) ATE239790T1 (no)
AU (1) AU661360B2 (no)
CA (2) CA2121798C (no)
DE (2) DE69233051T2 (no)
DK (3) DK0822199T3 (no)
ES (2) ES2227513T5 (no)
FI (2) FI116850B (no)
HK (1) HK1019343A1 (no)
NO (2) NO317625B1 (no)
WO (1) WO1993008207A1 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
DK0679191T3 (da) * 1993-01-22 2004-04-13 Immunex Corp Påvisning og behandling af mutationer i et CD40-ligand-gen
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
ES2143553T3 (es) * 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
AU7643094A (en) * 1993-09-02 1995-03-22 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
AU680102B2 (en) * 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
DK0763057T3 (da) 1994-04-28 2006-03-27 Boehringer Ingelheim Pharma Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
DE69622259T2 (de) * 1995-03-01 2003-03-27 Immunex Corp., Seattle Cd40 bindendes protein zur stimulierung der immunantwort
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
DE69631331T2 (de) * 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
WO1997000895A1 (en) * 1995-06-22 1997-01-09 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP2000512541A (ja) * 1996-06-14 2000-09-26 ユニバーシティ オブ ワシントン 吸収力が向上した差違抽出装置
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2314695A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
AR023482A1 (es) * 1999-04-16 2002-09-04 Hoffmann La Roche Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
RU2270691C2 (ru) 2000-05-12 2006-02-27 Бет Израел Диконесс Медикал Сентер, Инк. Композиции и способы достижения иммунной супрессии
ATE327004T1 (de) 2000-10-02 2006-06-15 Chiron Corp Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
KR20050101554A (ko) 2003-02-14 2005-10-24 바이오겐 아이덱 엠에이 인코포레이티드 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터
GEP20105059B (en) 2004-07-26 2010-08-10 Biogen Idec Inc Anti-cd154 antibodies
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
ATE489455T1 (de) 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
CN101663390B (zh) 2006-09-13 2013-10-23 Abbvie公司 使用非动物源水解产物的分批补料细胞培养方法
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
CA2698809C (en) 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
EP2214840B1 (en) 2007-10-30 2015-05-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
PT2501822T (pt) 2009-11-17 2017-10-18 Squibb & Sons Llc Métodos para produção de proteínas melhorada
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
BR112015019283B1 (pt) 2013-02-14 2023-12-19 The Board Of Trustees Of The University Of Arkansas Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
IL300591A (en) 2016-05-11 2023-04-01 Amgen Inc Direct selection of cells expressing high levels of heteromeric proteins using intergenic glutamine synthetase complementation vectors
IL313003A (en) 2017-02-27 2024-07-01 Shattuck Labs Inc Chimeric proteins based on TIGIT and LIGHT
BR112019017713A2 (pt) * 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
ES2227513T5 (es) 2009-04-01
NO320073B1 (no) 2005-10-17
WO1993008207A1 (en) 1993-04-29
EP0667901A4 (en) 1995-06-22
JP2877788B2 (ja) 1999-03-31
EP0897983A3 (en) 1999-03-17
EP0667901B1 (en) 2004-08-18
FI116828B (fi) 2006-03-15
CA2312667C (en) 2002-11-19
DE69233051T2 (de) 2004-03-11
EP0667901A1 (en) 1995-08-23
CA2312667A1 (en) 1993-04-29
NO941422D0 (no) 1994-04-19
NO941422L (no) 1994-06-27
AU3122693A (en) 1993-05-21
DK0667901T4 (da) 2008-11-10
CA2121798A1 (en) 1993-04-29
HK1019343A1 (en) 2000-02-03
EP0897983B1 (en) 2003-05-07
NO980030L (no) 1998-01-05
NO317625B1 (no) 2004-11-29
ATE274055T1 (de) 2004-09-15
FI941837A0 (fi) 1994-04-20
FI981765A0 (fi) 1998-08-17
ATE239790T1 (de) 2003-05-15
DK0822199T3 (da) 2004-12-27
DK0667901T3 (da) 2004-12-27
DE69233051D1 (de) 2003-06-12
DE69233402D1 (de) 2004-09-23
DE69233402T3 (de) 2009-06-25
DE69233402T2 (de) 2005-09-15
AU661360B2 (en) 1995-07-20
EP0897983A2 (en) 1999-02-24
JP3308534B2 (ja) 2002-07-29
FI116850B (fi) 2006-03-15
ES2227513T3 (es) 2005-04-01
JPH07504083A (ja) 1995-05-11
FI941837A (fi) 1994-05-30
EP0667901B2 (en) 2008-10-15
ES2198025T3 (es) 2004-01-16
FI981765A (fi) 1998-08-17
JPH10150994A (ja) 1998-06-09
DK0897983T3 (da) 2003-08-11
CA2121798C (en) 2007-07-24
KR100283541B1 (ko) 2001-03-02

Similar Documents

Publication Publication Date Title
NO980030D0 (no) Monoklonale antistoffer som binder CD40-L
NL300387I1 (nl) Antilichaam tegen menselijke interleukine-6-receptor
DE68914244D1 (de) Monoklonaler Antikörper.
DK666389D0 (da) Monoklonalt antistof
CY2006001I2 (el) Ανθρωποποιημενο heregulin αντισωμα
DE3885355D1 (de) Monoklonale Antikörper.
GB2144147B (en) Monoclonal antibody having only one light chain which will bind a specific antigen
ATE162553T1 (de) Monoklonale antikörper gegen hepatitis-c-virus
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
DK49291D0 (da) Gramnegativ-bakterieendotoxinblokerende, monoklonale antistoffer
DK474189A (da) Monoklonalt antistof
NO890116D0 (no) Monoklonale antistoffer.
DE68910956D1 (de) Mit toxin modifizierter antikörper.
DE69023717D1 (de) Monoklonaler Antikörper.
DK413389A (da) Monoklonale antistoffer
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
NO924803D0 (no) Tumor-relatert monoklonalt antistoff 88bv59
DE69118827D1 (de) Antikörper gegen Hamsterimmunglobulinen
FI960566A0 (fi) Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
ITMI910660A0 (it) Anticorpi monoclonali come antidoti
DK220688D0 (da) Monoklonalt antistof
NO903788D0 (no) Monoklonalt antistoff mot protein c.

Legal Events

Date Code Title Description
MK1K Patent expired